Metraipolis › archive › dc_a42ff85bf056

Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria — Europe PMC PMID:36355850

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/36355850
DOI
10.1371/journal.pone.0276639
License (as archived)
CC0-1.0
Archived
2026-10-15T18:44:23.540Z
SHA-256 of the archived text
1c7d92d0ae68ffaea4720e4745697f3629aa2f8c83622e3d7ffa0754bada370a
Stable URL of this page
https://metraipolis.com/documento/dc_a42ff85bf056

How to cite

Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria — Europe PMC PMID:36355850 — Europe PMC (en), https://europepmc.org/article/MED/36355850 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_a42ff85bf056 (Metraipolis archive dc_a42ff85bf056, sha256 1c7d92d0ae68ffaea4720e4745697f3629aa2f8c83622e3d7ffa0754bada370a)
BibTeX
@misc{dca42ff85bf056,
  title = {Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria — Europe PMC PMID:36355850},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36355850},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_a42ff85bf056; sha256 1c7d92d0ae68ffaea4720e4745697f3629aa2f8c83622e3d7ffa0754bada370a},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36355850. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Hydroxyurea (HU) is an evidence-based therapy that is currently the most effective drug for sickle cell disease (SCD). HU is widely used in high-income countries with consequent reduction of morbidity and mortality. In Nigeria, HU is prescribed by physicians while nurses are mainly involved in counseling the patients to ensure adherence. The extent of utilization and the determinant factors have not been sufficiently evaluated in Nigeria. Objective: To assess the frequency of use of HU and factors affecting utilization among healthcare providers, patients, and caregivers for SCD. Methods: A questionnaire was administered online and in- person to assess the frequency of HU use and the factors that promote and limit its use. The data were analyzed by descriptive statistics using IBM SPSS software version 23 and the result was presented in frequency tables and percentages. Result: A total of 137 physicians, 137 nurses, and 237 patients/caregivers responded to the survey. The rate of prescription of HU by doctors in the past 6 months was 64 (46.7%), 43 (31.4%) nurses provided counseling and 36 (15.6%) patients were on HU. Among doctors, adequate knowledge (91.3%), clinical benefits and safety (94.8%), and inclusion of HU in management guidelines (86.9%) were motivators for prescribing it while inadequate knowledge (60.9%) and unawareness of treatment guidelines (68.6%) constituted barriers. Among nurses, reduction of crisis (91.6%) and safety (64.8%) were the major motivators while barriers were high cost (79.1%) and intensive monitoring (63.1%) of HU treatment. Among the patients, the major motivator was the reduction of crises (80.3%) while poor knowledge (93.2%), high cost of the drug (92.2%) while monitoring (91.2%), non-availability (87.7%) and side effects (83.9%) were the major barriers for the utilization of HU. Conclusion: HU prescription and utilization are still poor among healthcare providers and patients. Inadequate knowledge, non-availability and high cost of HU as well as unawareness of treatment guidelines constitute major barriers to prescription and utilization.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-11-10).
Identificativi: PMID 36355850 · PMCID PMC9682971 · DOI 10.1371/journal.pone.0276639.
Descrittori MeSH principali: Anemia, Sickle Cell; Physicians.
Pagina: https://europepmc.org/article/MED/36355850 — https://doi.org/10.1371/journal.pone.0276639. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-15T18:08:34.794Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.